N

Novavax

D
NVAX
USD
0.505
(5.8247%)
Market Closed
127,726.00
Volume
-0.15
EPS
-
Div Yield
-3.496183
P/E
1,468,859,137.83
Market Cap
Today
2.5713%
1 Week
-4.427%
1 Month
-29.586%
6 Months
99.240%
12 Months
29.590%
Year To Date
91.146%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
AEMD
0.0127
(3.2987%)
USD
MRNA
MRNA
-1.49
(-2.8776%)
USD
B
BNTX
-3.18
(-2.8654%)
USD
PFE
PFE
0.105
(0.3839%)
USD
JNJ
JNJ
-1.03
(-0.6528%)
USD
MRK
MRK
0.46
(0.4567%)
USD
AZN
AZN
0.835
(1.308%)
USD
I
INO
-0.13
(-2.2968%)
USD
V
VXRT
0.0125
(1.7576%)
USD
C
CODX
-0.035
(-2.8926%)
USD
C
CEMI
0.022
(6.4706%)
USD
A
ALT
0.155
(2.1218%)
USD

Title:
Novavax

Sector:
Healthcare
Industry:
Biotechnology
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Do you need help or have a question?
Contact Us